UNSPSC 51141570: Riluzole

This classification denotes an anticonvulsant agent with the molecular formula C8H5F3N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7LJ087RS6F, chemically known as 2-benzothiazolamine, 6-(trifluoromethoxy)- but generally known as riluzole, which bears US NIH Compound Identifier 5070. European Medicines Agency schedules Riluzole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10319MIG.

UNSPSC 51141570 Riluzole is a Commodity code that nominally addresses a specific pharmaceutical product, but the recent state and local solicitation activity tagged to this code does not align with riluzole procurement. Instead, the opportunities reflect broader pharmaceutical sourcing — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs. State and local health agencies, cooperative purchasing alliances, and public health departments are the primary issuing bodies, with procurement structured through both individual agency RFPs and cooperative purchasing vehicles that extend across multiple jurisdictions.

The most significant recent activity appears in two tracks. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, structured to serve state and local government facilities across participating jurisdictions including Oregon and distributed through three authorized wholesalers. Seminole County, Florida, posted an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: the posted date and due date appear inconsistent in the source). The Texas Health and Human Services Commission issued a preliminary RFI in April 2026 exploring vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, representing early-stage market intelligence gathering prior to formal RFP issuance. Geographic spread includes Florida, Minnesota, Texas, and Oregon, with the cooperative purchasing model extending the geographic reach beyond single jurisdictions. The code shows activity but limited direct alignment with riluzole; vendors pursuing this code should verify that their product scope matches the actual pharmaceutical categories being solicited in each specific opportunity.